Literature DB >> 15673695

Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II.

Michael Haase1, Rinaldo Bellomo, Jens Rocktaeschel, Sabine Ziemer, Holger Kiesewetter, Stanislao Morgera, Hans-H Neumayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673695     DOI： 10.1093/ndt/gfh544

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  16 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Phlegmasia cerulean dolens: complication of femoral vein catheterization.

Authors:  M Hari Krishna Reddy; B Sangeetha; M Aruna; V Sarat Chandra; Anil C Venkata Kumar; R Ram; V Sivakumar
Journal:  CEN Case Rep       Date:  2016-05-20

3.  Acute oxygenator failure: a new presentation of heparin-induced thrombocytopenia in a patient undergoing venovenous extracorporeal membrane oxygenation support.

Authors:  Robert A Ratzlaff; Juan G Ripoll; Lena L Kassab; Jose L Diaz-Gomez
Journal:  BMJ Case Rep       Date:  2016-12-16

4.  Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients.

Authors:  Chieh Kuo; Chiang-Chin Tsai; Chien-An Chen; Yueh-Feng Tsai; Yen-Hsun Chen
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

5.  Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors:  Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

6.  Significant association of anti-platelet factor 4/heparin antibody with cardiovascular disease in hemodialysis patients: a longitudinal 7-year study.

Authors:  Chi-Chu Liu; Li-Ping Chou; Tsang-Shan Chen; Chien-An Chen; Yueh-Feng Tsai
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

7.  Anti-platelet factor 4/heparin antibody is associated with progression of peripheral arterial disease in hemodialysis patients.

Authors:  Yen-Hsun Chen; Kao-Chang Lin; Yueh-Feng Tsai; Lai-King Yu; Li-Hsueh Huang; Chien-An Chen
Journal:  Int Urol Nephrol       Date:  2015-07-22       Impact factor: 2.370

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

9.  Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.

Authors:  Xianxuan Zhou; Lingyun Li; Robert J Linhardt; Jian Liu
Journal:  FEBS J       Date:  2013-03-06       Impact factor: 5.542

Review 10.  New concepts in heparin-induced thrombocytopenia: diagnosis and management.

Authors:  Sarah A Spinler
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.